95.23 - 97.14
55.47 - 103.81
1.63M / 1.81M (Avg.)
55.57 | 1.74
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-15.05%
Negative revenue growth while OR stands at 9.92%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-15.05%
Negative gross profit growth while OR is at 10.18%. Joel Greenblatt would examine cost competitiveness or demand decline.
-31.12%
Negative EBIT growth while OR is at 15.15%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-31.12%
Negative operating income growth while OR is at 7.56%. Joel Greenblatt would press for urgent turnaround measures.
-25.48%
Negative net income growth while OR stands at 26.20%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
171.04%
EPS growth above 1.5x OR's 21.43%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
171.04%
Diluted EPS growth above 1.5x OR's 21.43%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.05%
Negative OCF growth while OR is at 11.49%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-185.05%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
35.12%
10Y revenue/share CAGR under 50% of OR's 191.83%. Michael Burry would suspect a lasting competitive disadvantage.
35.12%
5Y revenue/share CAGR 1.25-1.5x OR's 29.95%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
15.00%
Positive 3Y CAGR while OR is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-224.40%
Negative 3Y OCF/share CAGR while OR stands at 22738.42%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.74%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-29.74%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-31.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.53%
AR growth well above OR's 8.62%. Michael Burry fears inflated revenue or higher default risk in the near future.
17.35%
Inventory growth of 17.35% while OR is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
-13.66%
Negative asset growth while OR invests at 3.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-23.19%
We have a declining book value while OR shows 5.86%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-163.74%
We cut SG&A while OR invests at 19.74%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.